Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Cristina Guardia"'
Autor:
Hila Avisar, Cristina Guardia-Laguarta, Matthew Surface, Nikos Papagiannakis, Matina Maniati, Roubina Antonellou, Dimitra Papadimitriou, Christos Koros, Aglaia Athanassiadou, Serge Przedborski, Boaz Lerner, Leonidas Stefanis, Estela Area-Gomez, Roy N. Alcalay
Publikováno v:
npj Parkinson's Disease, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Lipid profiles in biological fluids from patients with Parkinson’s disease (PD) are increasingly investigated in search of biomarkers. However, the lipid profiles in genetic PD remain to be determined, a gap of knowledge of particular inte
Externí odkaz:
https://doaj.org/article/83b6cfbe26d145959efe4f680aa04238
Autor:
Yuhui Liu, Cristina Guardia-Laguarta, Jiang Yin, Hediye Erdjument-Bromage, Brittany Martin, Michael James, Xuejun Jiang, Serge Przedborski
Publikováno v:
Cell Reports, Vol 20, Iss 1, Pp 30-39 (2017)
Along with Parkin, PINK1 plays a critical role in maintaining mitochondrial quality control. Although PINK1 is expressed constitutively, its level is kept low in healthy mitochondria by polyubiquitination and ensuing proteasomal degradation of its ma
Externí odkaz:
https://doaj.org/article/c11d93ee72934d9882e3285305abd642
Autor:
Joan Albanell, Ana Rovira, Atanasio Pandiella, Federico Rojo, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles, Mohammad A. Sabbaghi, Elena Gavilán, Sandra Zazo, Francisco Javier Sánchez-Martín, Beatriz Morancho, Cristina Guardia, Mengjuan Qin, Silvia Menéndez, Oriol Arpí-Llucià, Sara García-Alonso, Anna Hernández-Prat, David Casadevall
Supplementary Figure from mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::367d536375661e6114b195b210a0e834
https://doi.org/10.1158/1541-7786.22527555.v1
https://doi.org/10.1158/1541-7786.22527555.v1
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Luca Gianni, Atanasio Pandiella, Joaquin Arribas, Pilar Eroles, Ana Lluch, Belen Lloveras, Juan Madoz-Gúrpide, Raul Peña, MohammadA Sabbaghi, Luis Soria-Jiménez, Juan Carlos Montero, Sonia Servitja, Matteo Dugo, Barbara Galbardi, David Casadevall, Silvia Menendez, Oriol Arpí-LLucià, Giampaolo Bianchini, Cristina Guardia
Supplementary Figure 1 shows generation and cell-lineage characterization of primary CAF cultures derived from HER2-positive breast cancer patient biopsies. Moreover, it also shows NRG1 staining in two FFPE-associated patient samples from which prima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de3a2bdc1908e12f3dcd2d5f68fb4a4
https://doi.org/10.1158/1078-0432.22480880
https://doi.org/10.1158/1078-0432.22480880
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Luca Gianni, Atanasio Pandiella, Joaquin Arribas, Pilar Eroles, Ana Lluch, Belen Lloveras, Juan Madoz-Gúrpide, Raul Peña, MohammadA Sabbaghi, Luis Soria-Jiménez, Juan Carlos Montero, Sonia Servitja, Matteo Dugo, Barbara Galbardi, David Casadevall, Silvia Menendez, Oriol Arpí-LLucià, Giampaolo Bianchini, Cristina Guardia
Supplementary Figure 3 shows how trastuzumab plus pertuzumab, but not trastuzumab alone, overcome NRG1 enhanced pro-survival signaling in HER2-positive breast cancer cells and in ex vivo tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017b90a6b5ec6f6ff3436b320665813a
https://doi.org/10.1158/1078-0432.22480874.v1
https://doi.org/10.1158/1078-0432.22480874.v1
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Atanasio Pandiella, Ana Lluch, Ignasi Tusquets, Joaquin Arribas, Pilar Eroles, Juan Madoz-Gúrpide, Paula González-Alonso, Cristina Chamizo, Sandra Zazo, Maria Martínez-García, Aura Muntasell, Marta Salido, Laia Serrano, Montserrat Arumi-Uria, Silvia Menendez, Sara García-Alonso, Oriol Arpí, Sonia Servitja, Cristina Guardia, Gabriel Gil-Gómez, MohammadA Sabbaghi
Effects of T-DM1 on 750 cyclin B1 (CCNB1) mRNA expression in T751 DM1 sensitive and resistant breast cancer cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::507875c041da47b06c113042ab33150a
https://doi.org/10.1158/1078-0432.22463774.v1
https://doi.org/10.1158/1078-0432.22463774.v1
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Atanasio Pandiella, Ana Lluch, Ignasi Tusquets, Joaquin Arribas, Pilar Eroles, Juan Madoz-Gúrpide, Paula González-Alonso, Cristina Chamizo, Sandra Zazo, Maria Martínez-García, Aura Muntasell, Marta Salido, Laia Serrano, Montserrat Arumi-Uria, Silvia Menendez, Sara García-Alonso, Oriol Arpí, Sonia Servitja, Cristina Guardia, Gabriel Gil-Gómez, MohammadA Sabbaghi
Supplementary Figure legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8100eed542345710b968b848c46b8b81
https://doi.org/10.1158/1078-0432.22463768.v1
https://doi.org/10.1158/1078-0432.22463768.v1
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Luca Gianni, Atanasio Pandiella, Joaquin Arribas, Pilar Eroles, Ana Lluch, Belen Lloveras, Juan Madoz-Gúrpide, Raul Peña, MohammadA Sabbaghi, Luis Soria-Jiménez, Juan Carlos Montero, Sonia Servitja, Matteo Dugo, Barbara Galbardi, David Casadevall, Silvia Menendez, Oriol Arpí-LLucià, Giampaolo Bianchini, Cristina Guardia
Supplementary Table 1 shows main clinical-pathological characteristics of HER2-positive breast cancer patients whom primary CAF cultures were derived from.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bc0b46650f2d70f8eb66d55afbecf5
https://doi.org/10.1158/1078-0432.22480865.v1
https://doi.org/10.1158/1078-0432.22480865.v1
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Atanasio Pandiella, Ana Lluch, Ignasi Tusquets, Joaquin Arribas, Pilar Eroles, Juan Madoz-Gúrpide, Paula González-Alonso, Cristina Chamizo, Sandra Zazo, Maria Martínez-García, Aura Muntasell, Marta Salido, Laia Serrano, Montserrat Arumi-Uria, Silvia Menendez, Sara García-Alonso, Oriol Arpí, Sonia Servitja, Cristina Guardia, Gabriel Gil-Gómez, MohammadA Sabbaghi
Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: HER2-positive breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6060f18e6822572a897febf82a397971
https://doi.org/10.1158/1078-0432.c.6525512.v1
https://doi.org/10.1158/1078-0432.c.6525512.v1
Autor:
Joan Albanell, Ana Rovira, Federico Rojo, Luca Gianni, Atanasio Pandiella, Joaquin Arribas, Pilar Eroles, Ana Lluch, Belen Lloveras, Juan Madoz-Gúrpide, Raul Peña, MohammadA Sabbaghi, Luis Soria-Jiménez, Juan Carlos Montero, Sonia Servitja, Matteo Dugo, Barbara Galbardi, David Casadevall, Silvia Menendez, Oriol Arpí-LLucià, Giampaolo Bianchini, Cristina Guardia
Supplementary Figure 2 shows how NRG1/CAFs, but not normal mammary fibroblasts, mediate trastuzumab resistance in HER2-positive breast cancer cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15931ffdf84e214d198d7fce558d8476
https://doi.org/10.1158/1078-0432.22480877
https://doi.org/10.1158/1078-0432.22480877